Works matching AU Kim, Dae-Jung

Results: 118
    1
    2
    3
    4
    5
    6
    7
    8
    9
    10
    11
    12
    13
    14

    Lower risk of cardiovascular events and death associated with initiation of sodium‐glucose cotransporter‐2 inhibitors versus sulphonylureas: Analysis from the CVD‐REAL 2 study.

    Published in:
    Diabetes, Obesity & Metabolism, 2023, v. 25, n. 8, p. 2402, doi. 10.1111/dom.15092
    By:
    • Goh, Su‐Yen;
    • Kosiborod, Mikhail N.;
    • Lam, Carolyn S. P.;
    • Cavender, Matthew A.;
    • Kohsaka, Shun;
    • Norhammar, Anna;
    • Birkeland, Kåre I.;
    • Holl, Reinhard W.;
    • Mauricio, Dídac;
    • Tangri, Navdeep;
    • Shaw, Jonathan E.;
    • Thuresson, Marcus;
    • Fenici, Peter;
    • Kim, Dae Jung
    Publication type:
    Article
    15
    16

    Lower cardiorenal risk with sodium‐glucose cotransporter‐2 inhibitors versus dipeptidyl peptidase‐4 inhibitors in patients with type 2 diabetes without cardiovascular and renal diseases: A large multinational observational study.

    Published in:
    Diabetes, Obesity & Metabolism, 2021, v. 23, n. 1, p. 75, doi. 10.1111/dom.14189
    By:
    • Birkeland, Kåre I.;
    • Bodegard, Johan;
    • Banerjee, Amitava;
    • Kim, Dae Jung;
    • Norhammar, Anna;
    • Eriksson, Jan W.;
    • Thuresson, Marcus;
    • Okami, Suguru;
    • Ha, Kyoung Hwa;
    • Kossack, Nils;
    • Mamza, Jil Billy;
    • Zhang, Ruiqi;
    • Yajima, Toshitaka;
    • Komuro, Issei;
    • Kadowaki, Takashi
    Publication type:
    Article
    17
    18
    19
    20
    21
    22
    23
    24
    25
    26
    27
    28
    29
    30
    31

    Independent Risk Factors for Mortality in Patients with Chronic Obstructive Pulmonary Disease Who Undergo Comprehensive Cardiac Evaluations.

    Published in:
    Respiration, 2015, v. 90, n. 3, p. 199, doi. 10.1159/000437097
    By:
    • ahn, Young-Hwan;
    • Lee, Keu Sung;
    • Park, Joo Hun;
    • Jung, Jin-Hee;
    • Lee, Miyeon;
    • Jung, Yun-Jung;
    • Chung, Wou Young;
    • Sheen, Seungsoo;
    • Park, Kwang Joo;
    • Kim, Dae Jung;
    • Kang, Dae Ryoung;
    • Lee, Jeong-Dong;
    • Yoon, Soojee;
    • Jin, Xiong Jie;
    • Yang, Hyoung-Mo;
    • Lim, Hong-Seok;
    • Park, Jin Sun;
    • Shin, Joon-Han;
    • Tahk, Seung-Jea
    Publication type:
    Article
    32
    33
    34
    35
    36
    37
    38
    39
    40
    41
    42
    43
    44

    Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study.

    Published in:
    Journal of Diabetes Investigation, 2023, v. 14, n. 3, p. 417, doi. 10.1111/jdi.13959
    By:
    • Kim, Dae Jung;
    • Sheu, Wayne H‐H;
    • Chung, Wook‐Jin;
    • Yabe, Daisuke;
    • Ha, Kyoung Hwa;
    • Nangaku, Masaomi;
    • Tan, Elise Chia‐Hui;
    • Node, Koichi;
    • Yasui, Atsutaka;
    • Lei, Weiyu;
    • Lee, Sunwoo;
    • Saarelainen, Laura;
    • Deruaz‐Luyet, Anouk;
    • Kyaw, Moe H;
    • Seino, Yutaka
    Publication type:
    Article
    45
    46

    Healthcare resource utilization in patients treated with empagliflozin in East Asia.

    Published in:
    Journal of Diabetes Investigation, 2022, v. 13, n. 5, p. 810, doi. 10.1111/jdi.13728
    By:
    • Sheu, Wayne H‐H;
    • Seino, Yutaka;
    • Tan, Elise Chia‐Hui;
    • Yabe, Daisuke;
    • Ha, Kyoung Hwa;
    • Nangaku, Masaomi;
    • Chung, Wook‐Jin;
    • Node, Koichi;
    • Yasui, Atsutaka;
    • Lei, Wei‐Yu;
    • Lee, Sunwoo;
    • Ustyugova, Anastasia;
    • Klement, Riho;
    • Deruaz‐Luyet, Anouk;
    • Kyaw, Moe H;
    • Kim, Dae Jung
    Publication type:
    Article
    47
    48
    49
    50